#canine osteosarcoma

Osteosarcoma: Beyond amputation and euthanasia

March 12, 2019

When a patient is diagnosed with osteosarcoma, we tend to focus on three options: • the “gold standard,” i.e. amputation with or without chemotherapy; • what many call palliative care, meaning pain medication and rest; or • euthanasia. But what if amputation is not an option? What if chemotherapy or radiation is out of the owner’s financial capabilities? Or a couple of medications are not enough to numb the pain? What if …

20-plus clinics to participate in expanded osteosarcoma vaccine clinical trial

September 6, 2018

Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy …

ELIAS presents preliminary canine osteosarcoma results at ACVIM

August 3, 2018

During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company’s new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated “impressive survival times and minimal side …

Canadian researchers team up to fight canine osteosarcoma

June 14, 2018

A group of researchers called the Dog Osteosarcoma Group–Biomarkers of Neoplasia (DOGBONe) at the University of Guelph in Ontario, Canada, have joined forces to determine more accurate ways of measuring bone cancer, with the main objective of identifying biomarkers to assess patients with canine osteosarcoma. The presentation of osteosarcoma in dogs is remarkably similar to that of humans, according to the Ontario Veterinary College (OVC); so much so that computers are unable to distinguish …

MAF awards Penn $775K to test osteosarcoma immunotherapy vaccine in dogs

April 20, 2018

Morris Animal Foundation (MAF) has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment that combines a molecule expressed by cancer cells with a modified live form of Listeria monocytogenes. A pilot study demonstrated this combination elicited a powerful, targeted immune response directed …

Aratana Therapeutics secures USDA conditional license for canine osteosarcoma vaccine

January 10, 2018

Aratana Therapeutics announced that its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the USDA Center for Veterinary Biologics for the treatment of dogs diagnosed with osteosarcoma, 1 year of age or older. The vaccine is a novel immunotherapy developed by using a listeria-based antigen delivery system licensed from Advaxis Inc. “Osteosarcoma is the most common primary bone tumor in dogs and, …
New on

Join VPN Plus+ today to get access to exclusive content like:

Is it time to upgrade your payment system?
Why creating a good flap matters
Photo op: How thermal imaging is helping keep pets healthy
Is immunotherapy the key to wiping out canine cancer?
Join Now!
COVID-19
N.C. pug tests positive for COVID-19
From the trenches: Veterinary musings from a pandemic-rattled brain
Veterinary professionals answer the call to arms
AVMA Convention cancelled due to COVID-19
COVID-19 myths debunked in webinar